| Klarity-C (U.S.N.L.M.) | ||
|---|---|---|
| Dosing | 1 drop bid 12 hours apart | |
| Chem Specs | cyclosporine 0.1% | |
| Quantities | 5.5 ml bottle, (10 bottles per box) | |
| Cost | 440.00 (box of 10) | |
| Class | peptide immunosuppressant | |
| Action | Calcineurin inhibitor, modulates T-cell function and increases goblet cell density. | |
| Usage | Indicated to increase tear production where tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. |
|
| Adverse Reactions | 17% to 22% report pain or burning on instillation with cyclosporine . | |
| Contraindications | Active ocular infections and hypersensitivity to any ingredients in the formulation. | |
| Pediatric use | Safety and efficacy not established in pediatric patients. Transplant recipients as young as one year of age have received cyclosporine with no unusual adverse effects. |
|
| Pregnancy | Embryo- and fetotoxic in rats and rabbits following oral administration at 5000 and 32000 times the normal numan dose. |
|
| Undetectable in blood following 0.05% ophthalmic administration. Can be used concomitantly with artificial tears, allowing 15 minutes between products. |
||
| 503-B preparation. Not FDA approved. Unpreserved emulsion contains chondroitin sulfate, glycerin, and other lubricants. It is speculated that the chondroitin could benefit corneas stressed with contact lens wear1. |
||